Verastem Oncology Licenses VS-7375, a New Oral KRAS G12D Inhibitor from GenFleet Therapeutics, and Shares Preliminary Clinical Data from Phase 1 Study in China.
Verastem Oncology has announced the early licensing of VS-7375, an oral KRAS G12D inhibitor, from GenFleet Therapeutics, along with preliminary clinical data from a Phase 1 study in China that shows promising results.
Company Information
Company
Verastem Oncology
Location
117 Kendrick Street, Suite 500
Needham, Massachusetts, United States
About
Verastem Oncology (Nasdaq: VSTM) is a late-stage development biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and FAK inhibition.
Fundz sees it the moment Verastem Oncology ships something new, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
NeedhamBiotechnologyHealthcareHealth CareTherapeuticsBiopharma